{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T17:09:34Z","timestamp":1790701774124,"version":"4.1.0"},"reference-count":60,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2016,1,1]],"date-time":"2016-01-01T00:00:00Z","timestamp":1451606400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2016,1]]},"DOI":"10.1038\/mt.2015.143","type":"journal-article","created":{"date-parts":[[2015,8,27]],"date-time":"2015-08-27T08:06:27Z","timestamp":1440662787000},"page":"175-183","source":"Crossref","is-referenced-by-count":27,"title":["Chronic Activation of Innate Immunity Correlates With Poor Prognosis in Cancer Patients Treated With Oncolytic Adenovirus"],"prefix":"10.1016","volume":"24","author":[{"given":"Kristian","family":"Taipale","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilkka","family":"Liikanen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juuso","family":"Juhila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riku","family":"Turkki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siri","family":"T\u00e4htinen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matti","family":"Kankainen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lotta","family":"Vassilev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ari","family":"Ristim\u00e4ki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anniina","family":"Koski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Kanerva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iulia","family":"Diaconu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Cerullo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"V\u00e4h\u00e4-Koskela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minna","family":"Oksanen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Linder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timo","family":"Joensuu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"Lundin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akseli","family":"Hemminki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1038\/mt.2015.143_bib1","doi-asserted-by":"crossref","first-page":"e28694","DOI":"10.4161\/onci.28694","article-title":"Trial Watch:: Oncolytic viruses for cancer therapy","volume":"3","author":"Pol","year":"2014","journal-title":"Oncoimmunology"},{"key":"10.1038\/mt.2015.143_bib2","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1038\/nbt.2287","article-title":"Oncolytic virotherapy","volume":"30","author":"Russell","year":"2012","journal-title":"Nat Biotechnol"},{"key":"10.1038\/mt.2015.143_bib3","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1038\/nrc3770","article-title":"Going viral with cancer immunotherapy","volume":"14","author":"Lichty","year":"2014","journal-title":"Nat Rev Cancer"},{"key":"10.1038\/mt.2015.143_bib4","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","article-title":"PD-1 Blockade in Tumors with Mismatch-Repair Deficiency","volume":"372","author":"Le","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1038\/mt.2015.143_bib5","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1038\/nm.2658","article-title":"RET, ROS1 and ALK fusions in lung cancer","volume":"18","author":"Takeuchi","year":"2012","journal-title":"Nat Med"},{"key":"10.1038\/mt.2015.143_bib6","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1158\/2326-6066.CIR-13-0028","article-title":"Immune heterogeneity of glioblastoma subtypes: extrapolation from the cancer genome atlas","volume":"1","author":"Doucette","year":"2013","journal-title":"Cancer Immunol Res"},{"key":"10.1038\/mt.2015.143_bib7","doi-asserted-by":"crossref","first-page":"5650","DOI":"10.1200\/JCO.2009.22.9054","article-title":"Personalized cancer therapy with selective kinase inhibitors: an emerging paradigm in medical oncology","volume":"27","author":"McDermott","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1038\/mt.2015.143_bib8","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","article-title":"Improved survival with vemurafenib in melanoma with BRAF V600E mutation","volume":"364","author":"Chapman","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1038\/mt.2015.143_bib9","doi-asserted-by":"crossref","first-page":"4877","DOI":"10.1200\/JCO.2009.26.5983","article-title":"Pilot study using molecular profiling of patients\u2019 tumors to find potential targets and select treatments for their refractory cancers","volume":"28","author":"Von Hoff","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1038\/mt.2015.143_bib10","doi-asserted-by":"crossref","first-page":"6373","DOI":"10.1158\/1078-0432.CCR-12-1627","article-title":"Personalized medicine in a phase I clinical trials program: the MD Anderson Cancer Center initiative","volume":"18","author":"Tsimberidou","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1038\/mt.2015.143_bib11","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1111\/jcpt.12008","article-title":"Impact of biomarker usage on oncology drug development","volume":"38","author":"Hayashi","year":"2013","journal-title":"J Clin Pharm Ther"},{"key":"10.1038\/mt.2015.143_bib12","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/s13045-014-0070-8","article-title":"Strategies for modern biomarker and drug development in oncology","volume":"7","author":"Smith","year":"2014","journal-title":"J Hematol Oncol"},{"key":"10.1038\/mt.2015.143_bib13","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1158\/0008-5472.CAN-11-2975","article-title":"Immune response is an important aspect of the antitumor effect produced by a CD40L-encoding oncolytic adenovirus","volume":"72","author":"Diaconu","year":"2012","journal-title":"Cancer Res"},{"key":"10.1038\/mt.2015.143_bib14","doi-asserted-by":"crossref","first-page":"4225","DOI":"10.1016\/j.vaccine.2009.03.074","article-title":"In situ adenovirus vaccination engages T effector cells against cancer","volume":"27","author":"Tuve","year":"2009","journal-title":"Vaccine"},{"key":"10.1038\/mt.2015.143_bib15","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.2174\/138920112800958913","article-title":"Oncolytic viruses for induction of anti-tumor immunity","volume":"13","author":"Tong","year":"2012","journal-title":"Curr Pharm Biotechnol"},{"key":"10.1038\/mt.2015.143_bib16","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1038\/sj.mt.6300031","article-title":"Toll-like receptor 9 triggers an innate immune response to helper-dependent adenoviral vectors","volume":"15","author":"Cerullo","year":"2007","journal-title":"Mol Ther"},{"key":"10.1038\/mt.2015.143_bib17","doi-asserted-by":"crossref","first-page":"2734","DOI":"10.1158\/1078-0432.CCR-12-2546","article-title":"Antiviral and antitumor T-cell immunity in patients treated with GM-CSF-coding oncolytic adenovirus","volume":"19","author":"Kanerva","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1038\/mt.2015.143_bib18","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/1479-5876-8-10","article-title":"Anti-viral state segregates two molecular phenotypes of pancreatic adenocarcinoma: potential relevance for adenoviral gene therapy","volume":"8","author":"Monsurr\u00f2","year":"2010","journal-title":"J Transl Med"},{"key":"10.1038\/mt.2015.143_bib19","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1038\/mt.2011.144","article-title":"Induction of interferon pathways mediates in vivo resistance to oncolytic adenovirus","volume":"19","author":"Liikanen","year":"2011","journal-title":"Mol Ther"},{"key":"10.1038\/mt.2015.143_bib20","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/mt.2014.218","article-title":"Case-control estimation of the impact of oncolytic adenovirus on the survival of patients with refractory solid tumors","volume":"23","author":"Kanerva","year":"2015","journal-title":"Mol Ther"},{"key":"10.1038\/mt.2015.143_bib21","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1038\/sj.cdd.4401707","article-title":"The brain within the tumor: new roles for axon guidance molecules in cancers","volume":"12","author":"Ch\u00e9dotal","year":"2005","journal-title":"Cell Death Differ"},{"key":"10.1038\/mt.2015.143_bib22","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1038\/nrc3005","article-title":"Novel roles for Slits and netrins: axon guidance cues as anticancer targets?","volume":"11","author":"Mehlen","year":"2011","journal-title":"Nat Rev Cancer"},{"key":"10.1038\/mt.2015.143_bib23","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/sj.icb.7100123","article-title":"Axon growth and guidance genes identify T-dependent germinal centre B cells","volume":"86","author":"Yu","year":"2008","journal-title":"Immunol Cell Biol"},{"key":"10.1038\/mt.2015.143_bib24","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1111\/j.1365-2567.2012.03587.x","article-title":"Regulation of B-cell responses by Toll-like receptors","volume":"136","author":"Browne","year":"2012","journal-title":"Immunology"},{"key":"10.1038\/mt.2015.143_bib25","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/cmi.2012.61","article-title":"TLR signaling in B-cell development and activation","volume":"10","author":"Hua","year":"2013","journal-title":"Cell Mol Immunol"},{"key":"10.1038\/mt.2015.143_bib26","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/nm.3089","article-title":"Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer","volume":"19","author":"Heo","year":"2013","journal-title":"Nat Med"},{"key":"10.1038\/mt.2015.143_bib27","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1200\/JCO.2014.58.3377","article-title":"Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma","volume":"33","author":"Andtbacka","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1038\/mt.2015.143_bib28","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.it.2009.04.002","article-title":"Is complement good or bad for cancer patients? A new perspective on an old dilemma","volume":"30","author":"Markiewski","year":"2009","journal-title":"Trends Immunol"},{"key":"10.1038\/mt.2015.143_bib29","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1046\/j.1365-2249.2003.02066.x","article-title":"Complement resistance of human carcinoma cells depends on membrane regulatory proteins, protein kinases and sialic acid","volume":"131","author":"Donin","year":"2003","journal-title":"Clin Exp Immunol"},{"key":"10.1038\/mt.2015.143_bib30","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1111\/j.1365-2249.2007.03507.x","article-title":"Down-regulation of CD55 and CD46 expression by anti-sense phosphorothioate oligonucleotides (S-ODNs) sensitizes tumour cells to complement attack","volume":"150","author":"Zell","year":"2007","journal-title":"Clin Exp Immunol"},{"key":"10.1038\/mt.2015.143_bib31","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1007\/s00262-005-0055-0","article-title":"Expression of the membrane complement regulatory protein CD59 (protectin) is associated with reduced survival in colorectal cancer patients","volume":"55","author":"Watson","year":"2006","journal-title":"Cancer Immunol Immunother"},{"key":"10.1038\/mt.2015.143_bib32","doi-asserted-by":"crossref","first-page":"2925","DOI":"10.1099\/vir.0.83142-0","article-title":"Species B adenovirus serotypes 3, 7, 11 and 35 share similar binding sites on the membrane cofactor protein CD46 receptor","volume":"88","author":"Fleischli","year":"2007","journal-title":"J Gen Virol"},{"key":"10.1038\/mt.2015.143_bib33","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/nm.2270","article-title":"Desmoglein 2 is a receptor for adenovirus serotypes 3, 7, 11 and 14","volume":"17","author":"Wang","year":"2011","journal-title":"Nat Med"},{"key":"10.1038\/mt.2015.143_bib34","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/nrc2618","article-title":"Microenvironmental regulation of metastasis","volume":"9","author":"Joyce","year":"2009","journal-title":"Nat Rev Cancer"},{"key":"10.1038\/mt.2015.143_bib35","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1136\/jclinpath-2011-200355","article-title":"Tumour-infiltrating macrophages and clinical outcome in breast cancer","volume":"65","author":"Mahmoud","year":"2012","journal-title":"J Clin Pathol"},{"key":"10.1038\/mt.2015.143_bib36","doi-asserted-by":"crossref","first-page":"3280","DOI":"10.1182\/blood-2012-04-421057","article-title":"Tumor-associated macrophages predict inferior outcomes in classic Hodgkin lymphoma: a correlative study from the E2496 Intergroup trial","volume":"120","author":"Tan","year":"2012","journal-title":"Blood"},{"key":"10.1038\/mt.2015.143_bib37","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1089\/hum.2013.123","article-title":"[(18)F]-fluorodeoxyglucose positron emission tomography and computed tomography in response evaluation of oncolytic adenovirus treatments of patients with advanced cancer","volume":"24","author":"Koski","year":"2013","journal-title":"Hum Gene Ther"},{"key":"10.1038\/mt.2015.143_bib38","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1038\/nri2314","article-title":"Interferon-inducible antiviral effectors","volume":"8","author":"Sadler","year":"2008","journal-title":"Nat Rev Immunol"},{"key":"10.1038\/mt.2015.143_bib39","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1084\/jem.20101158","article-title":"Type I interferon is selectively required by dendritic cells for immune rejection of tumors","volume":"208","author":"Diamond","year":"2011","journal-title":"J Exp Med"},{"key":"10.1038\/mt.2015.143_bib40","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1158\/2326-6066.CIR-14-0099","article-title":"STING contributes to antiglioma immunity via triggering type I IFN signals in the tumor microenvironment","volume":"2","author":"Ohkuri","year":"2014","journal-title":"Cancer Immunol Res"},{"key":"10.1038\/mt.2015.143_bib41","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1038\/nri1961","article-title":"Interferons, immunity and cancer immunoediting","volume":"6","author":"Dunn","year":"2006","journal-title":"Nat Rev Immunol"},{"key":"10.1038\/mt.2015.143_bib42","doi-asserted-by":"crossref","first-page":"e13859","DOI":"10.1371\/journal.pone.0013859","article-title":"Defects in innate immunity render breast cancer initiating cells permissive to oncolytic adenovirus","volume":"5","author":"Ahtiainen","year":"2010","journal-title":"PLoS One"},{"key":"10.1038\/mt.2015.143_bib43","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1172\/JCI31405","article-title":"Immune surveillance of tumors","volume":"117","author":"Swann","year":"2007","journal-title":"J Clin Invest"},{"key":"10.1038\/mt.2015.143_bib44","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.it.2012.10.007","article-title":"B regulatory cells in cancer","volume":"34","author":"Balkwill","year":"2013","journal-title":"Trends Immunol"},{"key":"10.1038\/mt.2015.143_bib45","doi-asserted-by":"crossref","first-page":"215471","DOI":"10.1155\/2014\/215471","article-title":"The roles of regulatory B cells in cancer","volume":"2014","author":"He","year":"2014","journal-title":"J Immunol Res"},{"key":"10.1038\/mt.2015.143_bib46","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/j.ccr.2014.04.026","article-title":"B cells regulate macrophage phenotype and response to chemotherapy in squamous carcinomas","volume":"25","author":"Affara","year":"2014","journal-title":"Cancer Cell"},{"key":"10.1038\/mt.2015.143_bib47","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/ni.2035","article-title":"T cell exhaustion","volume":"12","author":"Wherry","year":"2011","journal-title":"Nat Immunol"},{"key":"10.1038\/mt.2015.143_bib48","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.molmed.2013.07.006","article-title":"Is CD69 an effective brake to control inflammatory diseases?","volume":"19","author":"Gonz\u00e1lez-Amaro","year":"2013","journal-title":"Trends Mol Med"},{"key":"10.1038\/mt.2015.143_bib49","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1158\/2326-6066.CIR-13-0216","article-title":"CD4 T-cell subsets and tumor immunity: the helpful and the not-so-helpful","volume":"2","author":"Kim","year":"2014","journal-title":"Cancer Immunol Res"},{"key":"10.1038\/mt.2015.143_bib50","doi-asserted-by":"crossref","first-page":"6900","DOI":"10.1158\/0008-5472.CAN-13-1550","article-title":"Therapeutic PD-1 pathway blockade augments with other modalities of immunotherapy T-cell function to prevent immune decline in ovarian cancer","volume":"73","author":"Duraiswamy","year":"2013","journal-title":"Cancer Res"},{"key":"10.1038\/mt.2015.143_bib51","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/nature14292","article-title":"Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer","volume":"520","author":"Twyman-Saint Victor","year":"2015","journal-title":"Nature"},{"key":"10.1038\/mt.2015.143_bib52","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.it.2015.02.008","article-title":"Overcoming T cell exhaustion in infection and cancer","volume":"36","author":"Pauken","year":"2015","journal-title":"Trends Immunol"},{"key":"10.1038\/mt.2015.143_bib53","doi-asserted-by":"crossref","first-page":"4541","DOI":"10.1158\/1078-0432.CCR-13-1471","article-title":"Oncolytic virotherapy trials\u2013letter","volume":"19","author":"Hemminki","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1038\/mt.2015.143_bib54","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1002\/ijc.26216","article-title":"Integrin targeted oncolytic adenoviruses Ad5-D24-RGD and Ad5-RGD-D24-GMCSF for treatment of patients with advanced chemotherapy refractory solid tumors","volume":"130","author":"Pesonen","year":"2012","journal-title":"Int J Cancer"},{"key":"10.1038\/mt.2015.143_bib55","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1158\/0008-5472.CAN-11-3001","article-title":"Oncolytic immunotherapy of advanced solid tumors with a CD40L-expressing replicating adenovirus: assessment of safety and immunologic responses in patients","volume":"72","author":"Pesonen","year":"2012","journal-title":"Cancer Res"},{"key":"10.1038\/mt.2015.143_bib56","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1038\/mt.2012.115","article-title":"Ad3-hTERT-E1A, a fully serotype 3 oncolytic adenovirus, in patients with chemotherapy refractory cancer","volume":"20","author":"Hemminki","year":"2012","journal-title":"Mol Ther"},{"key":"10.1038\/mt.2015.143_bib57","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1038\/mt.2010.161","article-title":"Treatment of cancer patients with a serotype 5\/3 chimeric oncolytic adenovirus expressing GMCSF","volume":"18","author":"Koski","year":"2010","journal-title":"Mol Ther"},{"key":"10.1038\/mt.2015.143_bib58","doi-asserted-by":"crossref","first-page":"4467","DOI":"10.18632\/oncotarget.2901","article-title":"Immunological data from cancer patients treated with Ad5\/3-E2F-\u039424-GMCSF suggests utility for tumor immunotherapy","volume":"6","author":"Hemminki","year":"2015","journal-title":"Oncotarget"},{"key":"10.1038\/mt.2015.143_bib59","doi-asserted-by":"crossref","first-page":"e32871","DOI":"10.1371\/journal.pone.0032871","article-title":"SPECT\/CT imaging of hNIS-expression after intravenous delivery of an oncolytic adenovirus and 131I","volume":"7","author":"Rajecki","year":"2012","journal-title":"PLoS One"},{"key":"10.1038\/mt.2015.143_bib60","first-page":"291","article-title":"Quantification of histochemical staining by color deconvolution","volume":"23","author":"Ruifrok","year":"2001","journal-title":"Anal Quant Cytol Histol"}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001616303197?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001616303197?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,19]],"date-time":"2018-09-19T20:57:15Z","timestamp":1537390635000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525001616303197"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1]]},"references-count":60,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,1]]}},"alternative-id":["S1525001616303197"],"URL":"https:\/\/doi.org\/10.1038\/mt.2015.143","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.725749944.793522339","asserted-by":"object"}]},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2016,1]]}}}